Over the past two years, Merck (NYSE: MRK) has faced several challenges, resulting in a decline in the company's share price.

Thinking about whether Merck is a bargain or not? You’re not alone, plenty of investors are eager to know if now is the time to buy, hold, or stay away. Over the last month, Merck’s share price has ...

Merck’s MRK shares have risen 9.6% in a month. The company’s stock declined after it announced third-quarter results. Though it beat estimates for both earnings and sales, its blockbuster PD-L1 ...

Merck (MRK) shares have ticked higher this week, catching the interest of investors who follow the big names in healthcare.

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Merck has bullish valuation metrics and is trading above its 30-week EMA with bullish long-term momentum. Learn why MRK stock ...

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & ...

Merck agreed to pay $9.2 billion to purchase Cidara Therapeutics, looking to cash in on the firm's experimental flu treatment.

Merck & Co. Inc. (NYSE: MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ: CDTX) for $221.50 per share in ...